MX2023013248A - Anticuerpos anti-tmprss6 y sus usos. - Google Patents

Anticuerpos anti-tmprss6 y sus usos.

Info

Publication number
MX2023013248A
MX2023013248A MX2023013248A MX2023013248A MX2023013248A MX 2023013248 A MX2023013248 A MX 2023013248A MX 2023013248 A MX2023013248 A MX 2023013248A MX 2023013248 A MX2023013248 A MX 2023013248A MX 2023013248 A MX2023013248 A MX 2023013248A
Authority
MX
Mexico
Prior art keywords
tmprss6
antibodies
bind
disorder
humans
Prior art date
Application number
MX2023013248A
Other languages
English (en)
Spanish (es)
Inventor
Sarah J Hatsell
Andrew J Murphy
William Olson
Harvey Chin
Heinrich Emil Lob
Kei Saotome
Bojie Zhang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2023013248A publication Critical patent/MX2023013248A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023013248A 2021-05-11 2022-05-10 Anticuerpos anti-tmprss6 y sus usos. MX2023013248A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163187150P 2021-05-11 2021-05-11
PCT/US2022/028595 WO2022240877A1 (en) 2021-05-11 2022-05-10 Anti-tmprss6 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2023013248A true MX2023013248A (es) 2024-01-29

Family

ID=81927373

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013248A MX2023013248A (es) 2021-05-11 2022-05-10 Anticuerpos anti-tmprss6 y sus usos.

Country Status (14)

Country Link
US (2) US12448435B2 (enExample)
EP (1) EP4337695A1 (enExample)
JP (1) JP2024517931A (enExample)
KR (1) KR20240005894A (enExample)
CN (1) CN117730099A (enExample)
AU (1) AU2022274888A1 (enExample)
BR (1) BR112023023558A2 (enExample)
CA (1) CA3218455A1 (enExample)
CL (1) CL2023003331A1 (enExample)
CO (1) CO2023016777A2 (enExample)
IL (1) IL308375A (enExample)
MA (1) MA63064B1 (enExample)
MX (1) MX2023013248A (enExample)
WO (1) WO2022240877A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022240877A1 (en) 2021-05-11 2022-11-17 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof
WO2024211404A2 (en) * 2023-04-04 2024-10-10 Disc Medicine, Inc. Anti-tmprss6 antibodies and uses thereof
WO2025245434A1 (en) * 2024-05-24 2025-11-27 Disc Medicine, Inc. Compositions and methods for treating myelodysplastic syndromes (mds)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
CA2991637C (en) 2015-07-31 2022-07-05 Medimmune Limited Methods for treating hepcidin-mediated disorders
KR20220107252A (ko) * 2019-11-29 2022-08-02 키맵 리미티드 생리학적 철분 과다에 대한 치료
CN115243762A (zh) * 2020-04-07 2022-10-25 迈威(美国)生物治疗有限公司 抗tmprss6抗体及其用途
WO2022240877A1 (en) 2021-05-11 2022-11-17 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof

Also Published As

Publication number Publication date
JP2024517931A (ja) 2024-04-23
US20220411487A1 (en) 2022-12-29
BR112023023558A2 (pt) 2024-03-12
MA63064A1 (fr) 2024-02-29
IL308375A (en) 2024-01-01
CN117730099A (zh) 2024-03-19
AU2022274888A1 (en) 2023-12-07
US12448435B2 (en) 2025-10-21
CO2023016777A2 (es) 2023-12-11
EP4337695A1 (en) 2024-03-20
MA63064B1 (fr) 2025-02-28
CA3218455A1 (en) 2022-11-17
US20260098084A1 (en) 2026-04-09
KR20240005894A (ko) 2024-01-12
WO2022240877A1 (en) 2022-11-17
CL2023003331A1 (es) 2024-06-07

Similar Documents

Publication Publication Date Title
CO2023016777A2 (es) Anticuerpos anti-tmprss6 y sus usos
CL2024000378A1 (es) Anticuerpos anti-npr1 y usos de los mismos.
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
CL2018003563A1 (es) Anticuerpos anti-c5 y usos de los mismos.
UY39135A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
CL2021003132A1 (es) Anticuerpos que se unen a cd3 (divisional de solicitud n° 202101506)
CO2022009744A2 (es) Anticuerpos anti-trem2 y métodos para utilizarlos
ECSP20082648A (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
MX2021009722A (es) Anticuerpos anti-trem2 y metodos para utilizarlos.
CO2022017690A2 (es) Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos
AR073717A1 (es) Anticuerpos anti-notch2 de murino y humano, y metodos de uso
ECSP21052193A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
CL2025002112A1 (es) Anticuerpo anti-npr1; método de producción; y su uso.
ECSP22054464A (es) Anticuerpos anti-trem2 y m?todos para utilizarlos
CL2025003302A1 (es) Métodos de administración de anticuerpos que se unen a la interleuquina 13.
MX2022009475A (es) Anticuerpos contra klk5.
AR134275A1 (es) Anticuerpos cd24
AR121297A1 (es) Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de los mismos
AR117649A1 (es) Anticuerpos estabilizadores de trem2